Adoptive engineered t cell trials to achieve cancer killing

  • Description
  • Details
  • Subprojects
  • History
  • Relations
  • Publications
Project Title: Adoptive engineered t cell trials to achieve cancer killing
Project Number: CORDIS-106528
Project web address: Follow on CORDIS
Organization: University Of Manchester, United Kingdom, Manchester
Collaborators: University College London, GB
Karolinska Institutet, SE
Institut National De La Sante Et De La Recherche Medicale, FR
Erasmus Universitair Medisch Centrum Rotterdam, NL
Miltenyi Biotec Gmbh, DE
Fondazione Centro San Raffaele, IT
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis, NL
Royal Free Hospital, Royal Free Hampstead Nhs Trust, GB
Stockholms Lans Landsting, SE
The Christie Nhs Foundation Trust, GB
University College London Hospitalsnhs Foundation Trust, GB
Amsterdam Biotherapeutics Unit, NL
Adaptimmune Limited, GB
Ospedale San Raffaele Srl, IT
Cellular Therapeutics Limited, GB
Principal Investigators (PI): Greta Borg-Carbott, GB
William Lepetit, FR
Maria Von Witting, SE
Angela Ball, GB
Reno Debets, NL
Sabrina Schmitz, DE
Bastiaan Nuijen, NL
Dan Williams, GB
Sander Berghuis, NL
Rolf Kiessling, SE
Anna Jones, GB
Maria Rosa Pedrazzi, IT
Emma Clark, GB
Ryan Guest, GB
Robert Hawkins, GB
 
Project Description:
The aim of this research is to exploit technology for nucleic acid delivery through the clinical testing of adoptive engineered T cells to treat cancer. Recent innovative developments in cancer gene-immunotherapy have led to very encouraging early clinical results. However, the use of engineered T cells is a challenging and complex field with further development and more proof-of-principle trials needed. This proposal builds upon previous EU funded pre-clinical projects and comprises a multidisciplinary and translational research group with wide-ranging relevant expertise. Building on encouraging clinical results targeting NY-ESO-1 in melanoma and the availability of clinical grade vector, the consortium proposes to rapidly initiate two landmark studies in this field: the first to examine the activity of engineered T cells in oesophago-gastric cancer as an example of a hard to treat common epithelial cancer; the second to undertake a randomised phase II study to determine whether an optimised cell production system developed by the partners improves the current clinical response rates in patients with metastatic melanoma treated with NY-ESO-1 targeted T-cells. Success in these trials will enable the consortia and others to carryout larger trials and potentially approval of this type of therapy as a treatment for multiple cancer types. The inclusion of a major industrial partner focused on cell therapy technology and two SMEs focus on the delivery of cell therapy will facilitate future development of this area following these trials; indeed the project also includes plans to further automate and streamline cell processing to facilitate this development. This project would enhance European expertise and competitiveness in an important emerging market. The research will also support the European biotechnology industry which will be important for the exploitation of these therapies and the successful outcome of this project.
 
Project Terms:
scientific research
Project Title: Adoptive engineered t cell trials to achieve cancer killing
Project Number: CORDIS-106528
Project web address: Follow on CORDIS
Organization: University Of Manchester, United Kingdom, Manchester
Collaborators: University College London, GB
Karolinska Institutet, SE
Institut National De La Sante Et De La Recherche Medicale, FR
Erasmus Universitair Medisch Centrum Rotterdam, NL
Miltenyi Biotec Gmbh, DE
Fondazione Centro San Raffaele, IT
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis, NL
Royal Free Hospital, Royal Free Hampstead Nhs Trust, GB
Stockholms Lans Landsting, SE
The Christie Nhs Foundation Trust, GB
University College London Hospitalsnhs Foundation Trust, GB
Amsterdam Biotherapeutics Unit, NL
Adaptimmune Limited, GB
Ospedale San Raffaele Srl, IT
Cellular Therapeutics Limited, GB
Principal Investigators (PI): Greta Borg-Carbott, GB
William Lepetit, FR
Maria Von Witting, SE
Angela Ball, GB
Reno Debets, NL
Sabrina Schmitz, DE
Bastiaan Nuijen, NL
Dan Williams, GB
Sander Berghuis, NL
Rolf Kiessling, SE
Anna Jones, GB
Maria Rosa Pedrazzi, IT
Emma Clark, GB
Ryan Guest, GB
Robert Hawkins, GB
 
Project Categories:
Natural Sciences > Aging Diseases and Pathology > Cancer & related diseases > Malignant neoplasms (including in situ)
 
Other Information:
Fiscal Year: 2012
Project Start Date: 1 December 2012
Project End Date: 30 November 2017
Project program: FP7-HEALTH
 
Project Funding Information:
Funding Mechanism: CP-FP - Small or medium-scale focused research project
Year Funding Organization Total Funding, $
2012 European Research Council $9,086,917